Global Huntington's Disease Treatment Market 2026-2031 - Advancements in Novel Therapeutics to Drive Growth

Global Huntington's Disease Treatment Market 2026-2031 - Advancements in Novel Therapeutics to Drive Growth Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Huntington's Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global Huntington's disease treatment market was valued at USD 820 million in 2025 and is projected to increase from USD 890 million in 2026 to USD 1.31 billion by 2031. The market is expected to register a compound annual growth rate of 8.12% during the 2026-2031 forecast period, supported by advances in huntingtin-lowering therapies, wider adoption of VMAT2 inhibitors, accelerated regulatory pathways, and improving access to specialist care.

Huntingtin-Lowering Therapies Strengthen the Clinical Pipeline

Clinical progress across multiple therapeutic platforms is reshaping the Huntington's disease treatment market. WVE-003 achieved a reported 46% reduction in mutant huntingtin levels in cerebrospinal fluid while preserving wild-type huntingtin, addressing safety concerns associated with earlier approaches. Oral candidate PTC518 delivered reductions of up to 43% in blood huntingtin levels and slowed Total Motor Score progression by more than 70% at 12 months.

Commercial confidence in the disease-modifying pipeline has also increased. Novartis' USD 2.9 billion acquisition agreement involving PTC Therapeutics and PTC518 highlighted the perceived potential of huntingtin-lowering treatments. Regulatory willingness in the United States to consider huntingtin reduction as a surrogate endpoint could shorten development timelines, support biomarker-driven approvals, and accelerate the introduction of new Huntington's disease therapies.

Once-Daily VMAT2 Inhibitors Expand Symptom Management

Once-daily VMAT2 inhibitors continue to strengthen the symptomatic treatment segment. Teva Pharmaceutical Industries' alliance with Jiangsu Nhwa supported the approval of AUSTEDO in China, expanding access to chorea treatment and creating a foundation for future disease-modifying product launches in Asia. INGREZZA generated USD 2.3 billion in 2024, while alternative formulations have helped address administration challenges among patients with swallowing difficulties.

Symptomatic treatments accounted for 61.92% of the Huntington's disease treatment market in 2025. However, disease-modifying therapies are forecast to grow at a faster 15.84% CAGR through 2031. This expansion reflects progress in oral small molecules, antisense oligonucleotides, RNA interference candidates, and adeno-associated virus gene therapies. Disease-modifying products are projected to generate approximately USD 590 million by 2031 and represent nearly 45% of incremental market revenue growth.

Emerging care models may combine once-daily VMAT2 inhibitors with periodic huntingtin-lowering treatments, enabling clinicians to address motor symptoms while targeting long-term disease progression. Adoption will depend on clinical durability, selective lowering of mutant huntingtin, outpatient administration options, safety monitoring, and evidence demonstrating value to healthcare payers.

Oral Treatments Lead as Intravenous Therapies Gain Momentum

Oral formulations represented 54.05% of the Huntington's disease treatment market in 2025, benefiting from convenient administration and established prescribing patterns. Intravenous therapies are expected to grow at an 11.73% CAGR through 2031, driven by gene therapies and recurring antisense treatments requiring targeted central nervous system delivery. Intrathecal administration remains important for allele-selective candidates that require direct cerebrospinal fluid access.

Drug-delivery innovation is increasingly focused on pre-filled syringes, lyophilized powder kits, cold-chain management, and long-term patient monitoring. Hospitals are also expanding infusion capabilities and neurological monitoring infrastructure. As safety and durability evidence develops, intravenous therapies are forecast to approach 29.40% of the market by 2031.

High Treatment Costs and Limited Specialist Access Remain Key Challenges

The cost of advanced gene and cell therapies remains a major barrier to equitable access, with potential prices exceeding USD 1 million per patient. Healthcare payers are evaluating value-based reimbursement agreements and reinsurance models, but uneven adoption may restrict early commercialization in cost-sensitive markets. Limited specialist centers outside the United States and Europe, delayed diagnosis, and gaps in neurological infrastructure may also constrain market growth.

Additional growth factors include fast-track and orphan-drug designations in the United States and European Union, increasing diagnosis among aging populations, stronger rare-disease advocacy, and broader participation in clinical trials.

Regional Huntington's Disease Treatment Market Outlook

North America generated 38.20% of global market revenue in 2025. Its leadership is supported by expedited FDA pathways, concentrated specialist clinics, clinical trial activity, and payer adoption of VMAT2 inhibitors. Canada and Mexico are also collaborating with United States treatment centers to widen access to gene therapy studies and cross-border referrals.

Europe continues to benefit from regulatory coordination, multinational research programs, digital patient-support tools, and outcomes-based reimbursement pilots. Germany, the United Kingdom, and France remain leading centers for Huntington's disease clinical research, while improving neurological infrastructure in Eastern Europe is expected to support further expansion.

Asia-Pacific is forecast to be the fastest-growing regional market, advancing at a 14.55% CAGR through 2031. China's approval of a deuterated treatment, Japan's established rare-disease registries, clinician training initiatives in South Korea, and streamlined regulatory processes in Australia are supporting regional development. Physician education, patient mapping, remote monitoring, and accredited centers of excellence will remain central to growth in markets with lower diagnosed prevalence.

Latin America, the Middle East, and Africa remain emerging markets, but improving diagnostic capabilities, advocacy-led policy initiatives, and rising awareness are expected to create gradual opportunities as affordability and access barriers decline.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Incidence In Ageing-Cohort Populations

4.2.2 Accelerating HTT-Lowering Clinical Pipeline Breakthroughs

4.2.3 Commercial Launch Of Once-Daily VMAT2 Inhibitors In Asia

4.2.4 Fast-Track & Orphan Designations In US / EU

4.2.5 AI-Enabled Biomarker Discovery Improving Trial Success

4.2.6 ?eta-Blocker Repurposing Showing Disease-Modifying Signal

4.3 Market Restraints

4.3.1 Ultra-High Cost Of Gene & Cell Therapies

4.3.2 Limited Specialist Centres Outside North America & EU

4.3.3 Sub-Optimal Adherence To Symptomatic Poly-Pharmacy

4.3.4 Data-Safety Concerns For CRISPR In Neuronal Tissue

4.4 Porter's Five Forces

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitutes

4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Treatment Type

5.1.1 Symptomatic Treatments

5.1.1.1 VMAT2 Inhibitors

5.1.1.2 Antidopaminergics (Antipsychotics)

5.1.1.3 Antidepressants & Anxiolytics

5.1.1.4 Anticonvulsants / Others

5.1.2 Disease-Modifying Therapies

5.1.2.1 Gene Silencing / ASO

5.1.2.2 Gene Therapy (AAV, LNP etc.)

5.1.2.3 Stem-Cell Therapy

5.1.2.4 Small-Molecule HTT Modifiers

5.2 By Route of Administration

5.2.1 Oral

5.2.2 Intravenous

5.2.3 Intrathecal

5.2.4 Subcutaneous

5.3 By Distribution Channel

5.3.1 Hospital Pharmacies

5.3.2 Retail Pharmacies

5.3.3 Specialty & Online Pharmacies

5.4 By Stage of Disease

5.4.1 Pre-symptomatic / Prodromal

5.4.2 Early-Stage

5.4.3 Mid-Stage

5.4.4 Late-Stage

5.5 Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 United Kingdom

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 Japan

5.5.3.3 India

5.5.3.4 South Korea

5.5.3.5 Australia

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)

6.3.1 Pfizer Inc

6.3.2 Teva Pharmaceutical Industries

6.3.3 Neurocrine Biosciences

6.3.4 Alnylam Pharmaceuticals

6.3.5 Ionis Pharmaceuticals

6.3.6 Roche / Genentech

6.3.7 Novartis AG

6.3.8 uniQure

6.3.9 Sangamo Therapeutics

6.3.10 PTC Therapeutics

6.3.11 Prilenia Therapeutics

6.3.12 Wave Life Sciences

6.3.13 Sage Therapeutics

6.3.14 Biogen Inc.

6.3.15 Lundbeck

6.3.16 Azevan Pharmaceuticals

6.3.17 Voyager Therapeutics

6.3.18 IntraBio

6.3.19 Kyowa Kirin

6.3.20 Vaxxinity

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/a7oro6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.